Nephron Pharmaceuticals Corporation

Quick facts

Phase 3 pipeline

• T-2345 · Cardiovascular
  T-2345 is a small molecule drug that targets the renin-angiotensin system.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Nephron Pharmaceuticals Corporation portfolio CI brief
• Nephron Pharmaceuticals Corporation pipeline updates RSS